[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351434-105":59,"doc-detail-351434-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","reframing-the-paradigm-stereotactic-body-radiation-therapy-as-an-engineer-of-the-tumor-immune-microenvironment","Reframing the paradigm - stereotactic body radiation therapy as an engineer of the tumor immune microenvironment","","Stereotactic Body Radiation Therapy (SBRT) is shifting from a purely local ablative method toward a systemic immunomodulatory strategy, specifically by “engineering” the tumor immune microenvironment (TME). A narrative review synthesized literature published up to January 2026, focusing on biologically guided radiation schemes versus empirical combinations for overcoming resistance to immune checkpoint inhibitors (ICIs). Evidence supports a dose-dependent immunomodulatory window, with moderate hypofractionation potentially enhancing cGAS-STING type I interferon signaling while single high doses may attenuate immunity. Translation is constrained by organ-specific immune tolerance, motivating precision, triplet, and adaptive closed-loop approaches informed by liquid biopsy feedback.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/reframing-the-paradigm-stereotactic-body-radiation-therapy-as-an-engineer-of-the-tumor-immune-microenvironment/351434/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/reframing-the-paradigm-stereotactic-body-radiation-therapy-as-an-engineer-of-the-tumor-immune-microenvironment/351434.png","ImageObject",300,407,{"name":92,"@type":93},"Jordan Avery","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-08","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What paradigm shift does the review describe for SBRT?","Question",{"text":113,"@type":114},"SBRT is described as moving from a local ablative tool to a systemic immunomodulatory agent that can engineer the tumor immune microenvironment (TME).","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How does the review explain the relationship between SBRT dosing and immune effects?",{"text":118,"@type":114},"The review highlights a dose-dependent immunomodulatory window: moderate hypofractionation may optimally induce type I interferons via the cGAS-STING pathway, while single high doses can dampen immunity through TREX1 induction.",{"name":120,"@type":111,"acceptedAnswer":121},"Why are tailored combination strategies and adaptive protocols emphasized for clinical translation?",{"text":122,"@type":114},"Clinical translation is challenged by organ-specific immune tolerance and mixed outcomes with generic dosing schedules, so the review supports precision triplet therapies and adaptive “closed-loop” protocols guided by real-time liquid biopsy feedback.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},351434,1790146422,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},1099523882367,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","TYPE Review  \nPUBLISHED 31 March 2026  \nDOI 10.3389/fimmu.2026.1754669  \nOPEN ACCESS  \nEDITED BY  \nArchana Thakur,  \nUniversity of Virginia, United States  \nREVIEWED BY  \nDavid Akhavan,  \nUniversity of Kansas Medical Center, United States  \nRen Luo,  \nSichuan University, China  \n*CORRESPONDENCE  \nZhibin Yang  \n[yangzhibin@kmmu.edu.cn](yangzhibin@kmmu.edu.cn)[ ](yangzhibin@kmmu.edu.cn)Xianshuo Cheng  \n [chengxianshuo@sina.com](chengxianshuo@sina.com)[ ](chengxianshuo@sina.com)†These authors share ﬁrst authorship  \nRECEIVED 26 November 2025  \nREVISED 02 March 2026  \nACCEPTED 11 March 2026  \nPUBLISHED 31 March 2026  \nCITATION  \nWang X, Dong J, Fang S, Zhou Y, Cao R, Cheng X and Yang Z (2026) Reframing the paradigm: stereotactic body radiation therapy as an engineer of the tumor immune microenvironment. Front. Immunol. 17:1754669 .  \ndoi: 10.3389/fimmu.2026.1754669  \nCOPYRIGHT  \n© 2026 Wang, Dong, Fang, Zhou, Cao, Cheng and Yang. This is an open-access article distributed under the terms of the  \nCreative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nReframing the paradigm: stereotactic body radiation therapy as an engineer of the tumor immune microenvironment  \nXuehuan Wang 1†, Jianhua Dong 1†, Shaojun Fang 1, Yao Zhou 1, Rui Cao 2, Xianshuo Cheng 1* and Zhibin Yang 1*  \n1 Department of Colorectal Surgery, The Third Afﬁliated Hospital of Kunming Medical University/ Yunnan Tumor Hospital, Kunming, Yunnan, China, 2 Department of Anesthesiology, The Third Afﬁliated Hospital of Kunming Medical University, Kunming, Yunnan, China  \nBackground: Stereotactic Body Radiation Therapy (SBRT) is undergoing a paradigm shift from a purely local ablative tool to a systemic immunomodulatory agent. However, a signiﬁcant knowledge gap remains in understanding how to precisely“engineer” the tumor immune microenvironment (TME) to overcome resistance to immune checkpoint inhibitors (ICIs) . Current approaches often rely on empirical combinations rather than biologically guided strategies.  \nMethods: We conducted a comprehensive narrative review of literature published up to January 2026 using PubMed and Web of Science databases. Keywords included “SBRT,” “immunotherapy,” “cGAS-STING,” “abscopal effect,” and “tumor microenvironment.” We speciﬁcally synthesized evidence comparing the immunobiological impacts of ablative versus immunogenic doses (e.g., the TREX1-cGAS-STING axis) and analyzed organ-speciﬁc immune tolerance mechanisms. Results: Evidence suggests a “dose-dependent immunomodulatory window,”where moderate hypofractionation (e.g., 8 Gy x 3) optimally induces type Iinterferons via the cGAS-STING pathway, whereas single high doses (>12-18 Gy) may dampen immunity through TREX1 induction. Beyond direct cytotoxicity, SBRT remodels the TME by depleting regulatory T cells and recruiting effectors, though this is often counterbalanced by a biphasic inﬂux of MDSCs. Clinical translation faces challenges such as organ-speciﬁc immune tolerance, necessitating tailored triplet therapies.  \nConclusion: Future success lies in a precision medicine approach: moving beyond generic combinations to “organ-spec iﬁc triplets ” (e. g. , adding macrophage-targeting agents in liver disease) and implementing adaptive“closed-loop” protocols where real-time liquid biopsy feedback dictates the timing of the next SBRT pulse.  \nKEYWORDS  \ncGAS-STING pathway, immunotherapy, liquid biopsy, stereotactic body radiation therapy, tumor immune microenvironment  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \n1 Introduction  \nStereotactic Body Radiation Therapy (SBRT) has historically been deﬁned by its physical precision and ablative potenc","cbCainufHJKxuKKA","https://ap.wps.com/l/cbCainufHJKxuKKA","pdf",7518257,13,"English","# Introduction\n# The foundational immunobiology of SBRT: the in situ vaccine effect\n## Induction of immunogenic cell death and pro-inﬂammatory signal release","[{\"question\":\"What paradigm shift does the review describe for SBRT?\",\"answer\":\"SBRT is described as moving from a local ablative tool to a systemic immunomodulatory agent that can engineer the tumor immune microenvironment (TME).\"},{\"question\":\"How does the review explain the relationship between SBRT dosing and immune effects?\",\"answer\":\"The review highlights a dose-dependent immunomodulatory window: moderate hypofractionation may optimally induce type I interferons via the cGAS-STING pathway, while single high doses can dampen immunity through TREX1 induction.\"},{\"question\":\"Why are tailored combination strategies and adaptive protocols emphasized for clinical translation?\",\"answer\":\"Clinical translation is challenged by organ-specific immune tolerance and mixed outcomes with generic dosing schedules, so the review supports precision triplet therapies and adaptive “closed-loop” protocols guided by real-time liquid biopsy feedback.\"}]","Reframing the paradigm - stereotactic body radiation therapy as an engineer of the tumor immune microenvironment | PDF",1790094147,33,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0893842ac0ace55fd3f092d519ccd22b.webp",983,1389,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/104dbead80bc09be16eea8ac2993df82.webp",982,1388,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/678cad0c4c58efed12cdff4cf4b471da.webp",981,1386,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7f855e7ff747a4509447702328fdb171.webp",980,1385]